Screening for immune response against Dengue virus in Vietnamese non-human primates: implications for vaccine developers

Laura Lazo Vázquez1, Edith Suzarte Portal1, Jorge Castro Velazco1, Phuong Yen2, Le Trung Dung2, Lázaro Gil González1, Iris Valdés Prado1, Ernesto Marcos López1, Karem Cobas Acosta1, Nguyen Dang Hien2, Gerardo Guillén Nieto1 and Lisset Hermida Cruz1

One of the major problems faced for the development of a vaccine against Dengue virus is the lack of a suitable animal model. Although non-human primates do not show overt signs of disease, these animals develop viremia after the infection and are the best model to evaluate vaccine candidates against this pathogen. However, for that purpose, the screening of all animals is mandatory to discard those with previous natural immunity. The most common technique used in the screening is the plaque reduction neutralization test (PRNT). However, most recent studies points to the cell-mediated immunity (CMI) as an important player in the process of controlling Dengue virus (DENV) infections. Here we presented the results from the screening of 55 rhesus monkeys housed in an animal breeding facility at Quang Ninh province, Vietnam. We evaluated the neutralizing antibody response by PRNT and determined the levels of interferon γ (IFNγ)-secretion after the viral stimulation of monkey-peripheral blood mononuclear cells, by enzyme-linked immunosorbent assay (ELISA). We found no correspondence between PRNT and IFNγ-ELISA. In fact, 19 animals were positive only by IFNγ-ELISA. Moreover, to study the protective capacity of the CMI detected, three animals with positive response by IFNγ-ELISA and negative by PRNT were inoculated with an infective preparation of DENV-3 and, as a result, no viremia was detected during 10 days after the challenge. This fact points to the importance of screening non-human primates through a CMI assay together with PRNT. This procedure should discard those false-negative cases which would be protected after the viral challenge in the immunization schedule.

Clinical & Translational Immunology (2017) 6, e135; doi:10.1038/cti.2016.79; published online 24 March 2017

Dengue virus (DENV) is a flavivirus consisting of four serotypes named DENV-1, DENV-2, DENV-3 and DENV-4. These viruses are transmitted to humans through the bite of infected-mosquitoes. An estimated of 390 million infections and 96 million symptomatic cases of dengue occurs annually.1

The lack of a suitable animal model has hampered the progress of a dengue vaccine. Although several small-animal models have been developed over the years, none of them reproduces all the signs of the disease. Several species of non-human primates have been evaluated for DENV infection.2 These studies showed that these animals are susceptible to develop levels of viremia depending of the specie and serotype. Moreover, these animals generate a consistent antibody response, but do not show overt signs of disease.

To reliably evaluate a vaccine candidate against Dengue in non-human primates, it is critical to screen all animals looking for previous immunity against Dengue or another flavivirus. Usually, the screening consists in performing a Dengue immunoglobulin G (IgG)-enzyme-linked immunosorbent assay (ELISA) and a plaque reduction neutralization test (PRNT) and those animals without a positive humoral immune response are included in the study. However, most recent studies points to the cellular arm of the adaptive immune system as an important player in the process of controlling DENV infections.3-5 These evidences advise that the cell-mediated immunity (CMI) must be taken into account for the screening of non-human primates, since high levels of protection can be due to previous DENV-immunity and not to the evaluated vaccine candidate.

In this work, we present a preliminary evaluation of the influence of the cellular immune response (measured through the interferon γ (IFNγ) secretion by DENV-stimulated peripheral blood mononuclear cells (PBMC), detected by ELISA) in the viremia developed by Rhesus monkeys after an experimental infection with DENV-3. Moreover, we describe the results from serological studies of these animals and discuss the implications of the differences between PRNT and IFNγ-ELISA as techniques for selecting animals for a vaccination study. Finally, we analysed our seroprevalence results in the epidemiological context in the Asiatic region.
Table 1 Percentage of viral plaques reduction in African green monkey kidney (VERO) cells by monkey sera

| Mono | DENV-1 | DENV-2 | DENV-3 | DENV-4 | Mono | DENV-1 | DENV-2 | DENV-3 | DENV-4 |
|------|--------|--------|--------|--------|------|--------|--------|--------|--------|
| 1    | 19.71  | 52.21  | 0      | 0      | 29   | 41.61  | 4.41   | 42.86  | 21.05  |
| 2    | 0      | 19.12  | 3.57   | 0      | 30   | 41.61  | 48.53  | 35.71  | 28.57  |
| 3    | 8.76   | 48.53  | 39.29  | 28.57  | 31   | 27.01  | 0.74   | 35.71  | 6.02   |
| 4    | 0      | 19.12  | 17.86  | 28.57  | 32   | 52.55  | 15.44  | 35.71  | 32.33  |
| 5    | 1.46   | 22.79  | 21.43  | 39.85  | 33   | 41.61  | 37.50  | 0      | 0      |
| 6    | 0      | 33.82  | 39.29  | 21.05  | 34   | 34.31  | 37.50  | 0      | 0      |
| 7    | 12.41  | 44.85  | 39.29  | 6.02   | 35   | 19.71  | 22.79  | 21.43  | 6.02   |
| 8    | 52.55  | 33.82  | 64.29  | 32.33  | 36   | 41.61  | 0.74   | 35.71  | 28.57  |
| 9    | 34.31  | 26.47  | 32.14  | 0      | 37   | 34.31  | 22.79  | 53.57  | 2.26   |
| 10   | 12.41  | 26.47  | 35.71  | 36.09  | 38   | 30.66  | 11.76  | 35.71  | 9.77   |
| 11   | 1.46   | 8.09   | 28.57  | 36.09  | 39   | 16.06  | 30.15  | 35.71  | 9.77   |
| 12   | 0      | 53.57  | 28.57  | 40     | 40   | 16.06  | 26.47  | 3.57   | 0      |
| 13   | 23.36  | 33.82  | 21.43  | 21.05  | 41   | 45.26  | 55.88  | 32.14  | 0      |
| 14   | 41.61  | 22.79  | 25.00  | 6.02   | 42   | 8.76   | 4.41   | 25.00  | 2.26   |
| 15   | 5.11   | 0      | 21.43  | 0      | 43   | 19.71  | 30.15  | 57.14  | 0      |
| 16   | 16.06  | 4.41   | 39.29  | 0      | 44   | 48.91  | 0      | 21.43  | 0      |
| 17   | 56.20  | 30.15  | 17.86  | 9.77   | 45   | 37.96  | 26.47  | 3.57   | 0      |
| 18   | 41.61  | 19.12  | 10.71  | 9.77   | 46   | 41.61  | 11.76  | 53.57  | 2.26   |
| 19   | 23.36  | 37.50  | 28.57  | 21.05  | 47   | 23.36  | 22.79  | 28.57  | 6.02   |
| 20   | 23.36  | 30.15  | 17.86  | 9.77   | 48   | 37.96  | 0      | 25.00  | 0      |
| 21   | 37.96  | 33.82  | 25.00  | 0      | 49   | 30.66  | 26.47  | 0.00   | 24.81  |
| 22   | 19.71  | 30.15  | 10.71  | 0      | 50   | 34.31  | 26.47  | 39.29  | 24.81  |
| 23   | 5.11   | 44.85  | 28.57  | 0      | 51   | 52.55  | 41.18  | 53.57  | 36.09  |
| 24   | 27.01  | 22.79  | 25.00  | 17.29  | 52   | 12.41  | 15.44  | 39.29  | 2.26   |
| 25   | 34.31  | 0      | 0      | 6.02   | 53   | 30.66  | 22.79  | 50.00  | 39.85  |
| 26   | 19.71  | 26.47  | 35.71  | 32.33  | 54   | 37.96  | 37.50  | 28.57  | 9.77   |
| 27   | 37.96  | 4.41   | 21.43  | 0      | 55   | 41.61  | 37.50  | 21.43  | 21.05  |
| 28   | 19.71  | 15.44  | 32.14  | 0      | Percentagea | 7.3 | 3.6 | 12.7 | 0 |

Abbreviation: DENV, dengue virus.
*Percentage of animals with more than 50% viral plaques reduction per serotype. Values ≥50% are in bold. The unique serum dilution tested was 1:10.

RESULTS
Humoral immunity against Dengue
An amplified sandwich ELISA system was used to detect anti-DENV IgG antibodies. None of the animals showed antibody titers higher or equal to 1:100 against the four Dengue serotypes. However, 20% (11 out of 55) monkeys exhibited neutralizing antibody titers (≥1:10) at least against one serotype (Table 1). For each serotype the percentages of animals with neutralizing antibodies were 7.3% (4/55) for DENV-1, 3.6% (2/55) for DENV-2 and 12.7% (7/55) for DENV-3. Only 3.6% (2/55) were positive for both DENV-1 and DENV-3. None of the animals showed neutralizing antibodies against DENV-4 only. Note that 44/55 (80.0%) were negative for PRNT50.

Cellular immunity against Dengue measured by IFNγ-secretion after viral stimulus
PBMC from monkeys were stimulated with infective DENV to measure IFNγ secretion by ELISA (Figure 1a). As a result, 26/55 (47.3%) animals showed a positive response against one or more Dengue serotypes. In accordance with PRNT results, the positive response against DENV-3 was predominant (22/55; 40%) while a 30.1% of animals were positive for DENV-1 (Figure 1b). In addition, 25.4% were positive for DENV-2 and DENV-4. The 52.7% (29/55) of the animals were negative to all serotypes.

Viral challenge
To corroborate the results obtained in PRNT and IFNγ-ELISA, six animals were challenged by subcutaneous route with 104 p.f.u. of DENV-3. Three of them were negative by both techniques while the others were negative by PRNT and positive by IFNγ-ELISA. Two of the last ones had high levels of IFNγ-secretion after the stimulation with DENV-3 (monkey #31: 1346.7 pg ml−1; monkey #33: 1933.5 pg ml−1), whereas the rest one showed a low level (monkey #22: 738.3 pg ml−1). Blood was collected daily during 10 days to detect viremia. The presence of virus in serum samples was determined by plaque assay, inoculating 0.1 ml of undiluted serum onto VERO cell. As shown in Table 2, animals that were negative by PRNT and IFNγ-ELISA developed 3 days of viremia and an average viral load of 101.7 p.f.u. ml−1. In turn, monkeys negative by PRNT and positive by IFNγ-ELISA were completely protected.

DISCUSSION
In this study, we analyze the immune response against Dengue virus in 55 Rhesus monkeys captured on Reu island, from the Quang Ninh province, Vietnam, in 2012. We employed, in a first step, the PRNT, which is the technique most used in the screening of primates for immunization schedules and assessments of vaccine candidates against DENV.6–9 The results suggest that 80% of the animals from the island had not had prior contact with Dengue virus as they had no detectable neutralizing humoral response.

In a second step, we conducted an assay of IFNγ-secretion detected by ELISA, after PBMCs being in vitro-stimulated with the four DENV-serotypes. Unlike PRNT, which measures levels of circulating neutralizing antibodies, IFNγ-ELISA detects memory cellular immune response which is activated after the in vitro stimulation with the virus.
Unexpectedly, 40% of the animals showed a positive IFN\(_\gamma\) response following stimulation with DENV-3 and 47.3% showed a positive response on stimulation with at least one of the other serotypes. In general, we found no correspondence between both techniques; in fact, only seven animals showed neutralizing antibody response and IFN\(_\gamma\) secretion, four animals resulted positive only by PRNT and 19 were positive only by IFN\(_\gamma\)-ELISA. These results might be explained by the fact that after a natural infection, monkeys developed a low-level viremia and consequently, a low humoral immune response that declined in a few weeks. However, the memory T-cell response induced by the natural infection can be activated after an \textit{in vitro} stimulation of PBMCs thus secreting detectable levels of IFN\(_\gamma\).

Some studies suggest that the stimulation of PBMCs with infectious viruses can lead to IFN\(_\gamma\) response in the culture supernatant.\textsuperscript{10} In accordance, DENV-related flavivirus such as yellow fever virus can trigger TLR2, 7, 8, and 9 on dendritic cells\textsuperscript{11} and it is plausible that this could result in innate cytokine production that in turn, could stimulate IFN\(_\gamma\) responses by T cells in a non-virus-specific fashion. However, there are several published studies in which mouse-splenocytes and monkey-PBMCs from non-immunized groups did not secrete IFN\(_\gamma\) after the \textit{in vitro} stimulation with infectious DENV,\textsuperscript{3,12,13} suggesting specific antiviral responses. Future studies using splenocytes and/or PBMCs \textit{in vitro}-stimulated with overlapping peptides and infectious DENV will clarify this issue.

To study the protective capacity of the CMI detected, three animals with positive response by IFN\(_\gamma\)-ELISA and negative by PRNT, as well as three with negative responses by both techniques, were inoculated with an infective preparation of DENV-3. The first animals were protected while the others developed measurable viremia, during 3 days. This study evidences that cell-mediated immunity is able to protect animals from viral challenge, even without the presence of neutralizing antibodies detectable at the date of challenge.
erroneous inclusion of DENV-immune animals in an immunization schedule to evaluate a vaccine candidate against this pathogen could lead to wrong estimates of protection levels in vaccinated subjects or low viremia in placebo and hence, to misreading the results.

Recent studies point to the cellular arm of the adaptive immune system as an important player in the process of controlling DENV infections. Several different mouse experiments have demonstrated that CD8+ and even CD4+ T cells contribute to protection against DENV, decreasing the severity of disease manifestations or reducing the viral load in blood and other organs.14,15 Moreover, our group has developed CMI-based vaccine candidates using the recombinant capsid protein from DENV.3,12 Recently, these authors reported that the tetravalent formulation based on recombinant nucleocapsid-like particles from dengue viruses induces in both mice and monkeys an IFNγ-secreting cell response that significantly reduces viral load after challenge without the contribution of neutralizing antibodies.16

In our study, animals were not screened for another flavivirus such as Japanese encephalitis or Zika. However, if the detected IFNγ response was due to a DENV cross-reactive response induced by any flavivirus, the implication of our findings on DENV vaccine evaluation remains.

Two other points deserve discussion based on our results. First, the fact that although none of the animals showed detectable antiviral antibody titers by ELISA, 20% of the animals had neutralizing antibodies. Differences between the results obtained by both techniques (ELISA and PRNT) could be due to the initial dilution of sera used in the ELISA (1:100) which was 10 times higher than that evaluated in PRNT. In our experience, higher concentrations of sera in monkey IgG-ELISA increase unspecific interactions. Another possible explanation for these different results should be the viral strains used in each case; for ELISA we used neuro-adapted strains from infected mouse brain and for PRNT we used viral strains obtained from VERO cell culture.

Moreover, as we hypothesized above, DENV-natural infections in monkeys induce low neutralizing humoral response. Although it is known that these animals are involved in the natural cycle of transmission, only few studies describe DENV-seroprevalence in non-human primates. Kato et al.17 described a study in 100 cynomolgus monkeys from an animal breeding facility in the Philippines. A high incidence of DENV was detected since 21 animals were IgM positive and 19 monkeys resulted IgG positive.17 However, PRNT identified only nine positive sera and only one sample had neutralizing antibody titers higher that 1:100. In accordance with our results, there were animals (3) positive by PRNT while negative by IgG-ELISA. This study also supports the idea that there is no necessarily straightforward relationship between results from IgG-ELISA and PRNT. Anyway, taking into account our findings, we should expect that Kato et al. would find more positive animals if a CMI assay were used.

Second, the immune response detected in our study was predominantly directed against DENV-3, which suggests that this serotype circulated in Reu Island. According to Arima et al.,18 in 2012 Vietnam reported 86 026 clinical Dengue cases. All four serotypes were detected, with DENV-1 being the most common. However, in the same year, 9952 clinical dengue cases were reported in the neighbor Lao People’s Democratic Republic, which doubled the number of cases reported in 2011. Although all four serotypes were circulating, the predominant serotype was DENV-3. In general, all four serotypes were circulating in the Asian region in 2012, being serotypes 1 and 3 the most common. It is important to highlight that these serotypes have the highest percentage of identical amino acids (78.4%) in the envelope protein.19

In conclusion, our results suggest that for the evaluation of vaccine candidates in non-human primates it is not enough to screen animals by testing the immune response against Dengue only by ELISA and PRNT, as is done regularly. Besides, a CMI assay—stimulating with viral antigens—should be carried out to discard false-negative cases, which would be protected after the viral challenge in the immunization schedule.

**METHODS**

**Cells and viruses**

African monkey kidney cells (VERO) were received from the National Institute for Biological Standards and Control (NIBSC; NIBSC accession number: 011038). Cells were grown at 37°C in Eagle’s minimal essential medium supplemented with 10% fetal bovine serum.

The following virus strains were used for antibody detection and CMI: Hawaii (DENV-1), New Guinea C (DENV-2), H-87 (DENV-3) and H241 (DENV-4).20 For CMI viruses were concentrated by centrifugation at 80 000 g, 4 h at 4°C, homogenizing the resulting pellet in 1 ml of phosphate-buffered saline (Gibco, Paisley, UK). A mock preparation was prepared from the supernatant of uninfected VERO cells following a similar procedure. DENV-1 strain Jamaica CVI 1636 strain, DENV-2 SB8553 strain, DENV-3 Nicaragua 163/94 strain and DENV-4 Dominica 814669 strain were used for the PRNT. For the challenge study in monkeys, a viral stock was prepared with DENV-3 Nicaragua 163/94 strain.21

**Animals**

55 young monkeys (Macaca mulatta) were obtained from the Reu Island located in the northern province of Quang Ninh, Vietnam. The island is administered by the Centre for Research and Production of Vaccines and Biologicals (Polyvac), it has a total area of 22 hectares and a dense forest where living about a thousand of monkeys.

Animal group average were 18.4 months old and weight 2.09 kg and were 27 male and 28 female (Table 3). The study was carried out at Polyvac facilities in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals. Animals were maintained throughout the study in individual cages that permitted the evaluation and patterns conduct according to their species, size, age and sex. They were fed with fruits and vegetables and water was available ad libitum. All immunizations and blood extractions were performed using ketamine hydrochloride, 10 mg kg−1 body weight, and all efforts were made to minimize suffering.

**Monkeys challenge and viremia detection**

Six monkeys were subcutaneously inoculated in the upper arm with 107 p.f.u. of DENV-3. Blood was collected daily for 10 days to detect viremia. The presence of virus in serum samples was determined by direct plaque formation on VERO cells as previously described.22

**Measurement of humoral immune response**

The anti-DENV IgG antibodies induced by immunization were monitored by ELISA as previously described by Gil et al.,3 Titers were de-
and stimulated with the mock preparation or DENV at multiplicity of infection (MOI) of 0.5.

Concanavalin A (Sigma) was used as a positive control. In all experiments two wells were plated for each antigen. After 4 days of culture, culture supernatants were collected and stored at −80 °C. The culture supernatants were analyzed in duplicate for IFN-γ concentration by ELISA using monoclonal antibody pairs (Mabtech INF-γ; Nacka Strand, Sweden) and the protocol recommended by the manufacturer. The optical density at 492 nm in cells stimulated with mitogen was used to normalize data. Positive response was recommended by the manufacturer. The optical density at 492 nm in cells antibody pairs (Mabtech INF-γ; Nacka Strand, Sweden) and the protocol recommended by the manufacturer. The optical density at 492 nm in cells stimulated with mitogen was used to normalize data. Positive response was considered when the IFN-γ concentration value in the stimulated PBMCs was twice or higher than the IFN-γ concentration in cells without viral stimulus.

**CONFLICT OF INTEREST**

The authors declare no conflict of interest.

---

1. Bhatt S, Gething PW, Brady OJ, Messina JP, Farlow AW, Moyes CL et al. The global distribution and burden of dengue. Nature 2013; 496: 504–507.
2. Althouse BM, Durrin AP, Hanley KA, Halstead SB, Weaver SC, Cummings DA. Viral kinetics of primary dengue virus infection in non-human primates: a systematic review and individual pooled analysis. Virolgy 2014; 452–453: 237–246.
3. Gil L, Izquierdo A, Lazo L, Ambala P, Ochola L et al. Capsid protein: evidences about the partial protective role of neutralizing antibody-independent immunity against dengue in monkeys. Virology 2014; 456–457: 70–76.
4. Weiskopf D, Sette A. T-cell immunity to infection with dengue virus in humans. Front Immunol 2014; 5: 93.
5. Yauch LE, Zellweger RM, Kotton MF, Qutubuddin A, Sidney J, Peters B et al. A protective role for dengue virus-specific CD8+ T cells. J Immunol 2009; 182: 4865–4873.
6. Freire MS, Marchovsky RS, Almeida LF, Yamamura AM, Caride EC, Brindeiro PA et al. Wild dengue virus types 1, 2 and 3 viremia in rhesus monkeys. Mem Inst Oswaldo Cruz 2007; 102: 203–208.
7. Osorio JE, Brewo JN, Silengo SJ, Arguello J, Moldovan IR, Tary-Lehrmann M et al. Efficacy of a tetravalent chimeric dengue vaccine (DENVax) in Cynomolgus macaques. Am J Trop Med Hyg 2011; 84: 978–987.
8. Whitehead SS, Falgout B, Hanley KA, Blaney JJ Jr, Markoff L, Murphy BR. A live, attenuated dengue virus type 1 vaccine candidate with a 30-nucleotide deletion in the 3′ untranslated region is highly attenuated and immunogenic in monkeys. J Virol 2003; 77: 1653–1657.
9. Blaney JE Jr, Matro JM, Murphy BR, Whitehead SS. Recombinant, live-attenuated tetravalent dengue virus vaccine formulations induce a balanced, broad, and protective neutralizing antibody response against each of the four serotypes in rhesus monkeys. J Virol 2005; 79: 5516-5528.
10. Silfa MK, Leung DY, Hammarlund E, Raue HP, Simpson EL, Tofts S et al. Transcutaneous yellow fever vaccination of subjects with or without atopic dermatitis. J Allergy Clin Immunol 2014; 133: 439–447.
11. Guercy T, Benrouina S, Alkan S, Laasou Y, Gorden K, Flavell R et al. Yellow fever vaccine YF-17D activates multiple dendritic cell subsets through TLR2, 7, 8, and 9 to stimulate polyclonal immunity. J Exp Med 2006; 203: 413–424.
12. Gil L, Marcos E, Izquierdo A, Lazo L, Valdes I, Ambala P et al. The protein DIICC-2, aggregated with a specific oligodeoxynucleotide and adjuvanted in alum, protects mice and monkeys against DENV-2. Immuno Cell Biol 2016; 93: 57–66.
13. Suzarte E, Gil L, Valdes I, Marcos E, Lazo L, Izquierdo A et al. A novel tetravalent formulation combining the four aggregated domain III-capsid proteins from dengue viruses induces a functional immune response in mice and monkeys. Int Immunol 2019; 27: 367–379.
14. Yauch LE, Prestwood TR, May MM, Morar MM, Zellweger RM, Peters B et al. CD8+ T cells are not required for the induction of dengue virus-specific CD8+ T cell or antibody responses but contribute to protection after vaccination. J Immunol 2010; 185: 5405–5416.
15. Zellweger RM, Miller R, Eddy WE, White LJ, Johnston RE, Shresta S. Role of humoral versus cellular responses induced by a protective dengue vaccine candidate. PLoS Pathog 2013; 9: e1003723.
16. Gil L, Cobas K, Lazo L, Marcos E, Hernández L, Suzarte E et al. A tetravalent formulation based on recombinant nucleocapsid-like particles from dengue viruses induces a functional immune response in mice and monkeys. J Immunol 2016; 197: 3597–3606.
17. Kato F, Ishida Y, Kawagishi T, Kobayashi T, Hishiki T, Miura T et al. Natural infection of Cynomolgus monkeys with dengue virus occurs in epidemic cycles in the Philippines. J Gen Virol 2013; 94: 2202–2207.
18 Arima Y, Chiew M, Matsui T, Emerging Disease Surveillance and Response Team, Division of Health Security and Emergencies, World Health Organization Regional Office for the Western Pacific. Epidemiological update on the dengue situation in the Western Pacific Region, 2012. Western Pac Surveill Response J 2015; 6: 82-89.

19 Venkatachalam R, Subramaniam V. Homology and conservation of amino acids in E-protein sequences of dengue serotypes. Asian Pac J Trop Disease 2014; 4: 5573-5577.

20 CLARKE DH, Casals J. Techniques for hemagglutination and hemagglutination-inhibition with arthropod-borne viruses. Am J Trop Med Hyg 1958; 7: 561-573.

21 Valdes I, Hermida L, Gil L, Lazo L, Castro J, Martin J et al. Heterologous prime-boost strategy in non-human primates combining the infective dengue virus and a recombinant protein in a formulation suitable for human use. Int J Infect Dis 2010; 14: e377-e383.

22 Valdes I, Hermida L, Martin J, Menendez T, Gil L, Lazo L et al. Immunological evaluation in nonhuman primates of formulations based on the chimeric protein P64k-domain III of dengue 2 and two components of Neisseria meningitidis. Vaccine 2009; 27: 995-1001.

23 Morens DM, Halstead SB, Repik PM, Puthavathana P, Raybourne N. Simplified plaque reduction neutralization assay for dengue viruses by semimicro methods in BHK-21 cells: comparison of the BHK suspension test with standard plaque reduction neutralization. J Clin Microbiol 1985; 22: 250-254.

24 Kaufman BM, Summers PL, Dubois DR, Eckels KH. Monoclonal antibodies against dengue 2 virus E-glycoprotein protect mice against lethal dengue infection. Am J Trop Med Hyg 1987; 36: 427-434.